History of Diabetes Mellitus and Risk of Prostate Cancer in Physicians

American Journal of Epidemiology

Volumn 159, Issue 10, 2004, Pages 978-982

  Zhu, Kangmin ^a,e   Lee, I M ^b,c   Sesso, H D ^b,c   Buring, J E ^b,c   Levine, R S ^d   Gaziano, J M ^b  

^a United States Military Cancer Institute   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MEHARRY MEDICAL COLLEGE   (United States)

^e WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Case control studies; Diabetes mellitus; Prostatic neoplasms

Indexed keywords

INSULIN;

CANCER;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CANCER RISK; CASE CONTROL STUDY; DIABETES MELLITUS; EXERCISE; FEMALE; FOLLOW UP; HUMAN; LIFESTYLE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PHYSICIAN; PROSTATE CANCER; SMOKING; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COMORBIDITY; DIABETES MELLITUS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PHYSICIANS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; UNITED STATES;

EID: 2342630413     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/kwh139     Document Type: Article

References (45)

1. Jackson FL, Hutson JC. Altered responses to androgen in diabetic male rats. Diabetes 1984;33:819-24.
2. Ikeda K, Wada Y, Foster HE Jr, et al. Experimental diabetes-induced regression of the rat prostate is associated with an increased expression of transforming growth factor-beta. J Urol 2000;164:180-5.
3. Tesone M, Oliveira-Filho RM, Valle LB, et al. Androgen receptors in the diabetic rat. Diabetologia 1980;18:385-90.
4. Carlin BW. Impotence and diabetes. Metabolism 1988;37:19-21.
5. Hakim LS, Goldstein I. Diabetic sexual dysfunction. Endocrinol Metab Clin North Am 1996;25:379-400.
6. Shaneyfelt T, Husein R, Bubley G, et al. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 2000;18:847-53.
7. Thompson MM, Garland C, Barrett-Connor E, et al. Heart disease risk factors, diabetes, and prostatic cancer in an adult community. Am J Epidemiol 1989;129:511-17.
8. Rosenberg DJ, Neugut AI, Ahsan H, et al. Diabetes mellitus and the risk of prostate cancer. Cancer Invest 2002;20:157-65.
9. Giovannucci E, Rimm EB, Stampfer MJ, et al. Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control 1998;9:3-9.
10. Weiderpass E, Ye W, Vainio H, et al. Reduced risk of prostate cancer among patients with diabetes mellitus. Int J Cancer 2002;102:258-61.
11. Adami HO, McLaughlin J, Ekbom A, et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control 1991;2:307-14.
12. Henderson BE, Bogdanoff E, Gerkins VR, et al. Evaluation of cancer risk factors in a retirement community. Cancer Res 1974;34:1045-8.
13. La Vecchia C, Negri E, Franceschi S, et al. A case-control study of diabetes mellitus and cancer risk. Br J Cancer 1994;70:950-3.
14. Hsieh CC, Thanos A, Mitropoulos D, et al. Risk factors for prostate cancer: a case-control study in Greece. Int J Cancer 1999;80:699-703.
15. Kessler II. Cancer mortality among diabetics. J Natl Cancer Inst 1970;44:673-86.
16. Ragozzino M, Melton LJ 3rd, Chu CP, et al. Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J Chronic Dis 1982;35:13-19.
17. Steenland K, Nowlin S, Palu S. Cancer incidence in the National Health and Nutrition Survey I. Follow-up data: diabetes, cholesterol, pulse and physical activity. Cancer Epidemiol Biomarkers Prev 1995;4:807-11.
18. Will JC, Vinicor F, Calle EE. Is diabetes mellitus associated with prostate cancer incidence and survival? Epidemiology 1999;10:313-18.
19. O'Mara BA, Byers T, Schoenfeld E. Diabetes mellitus and cancer risk: a multisite case-control study. J Chronic Dis 1985;38:435-41.
20. Tavani A, Gallus S, Bosetti C, et al. Diabetes and the risk of prostate cancer. Eur J Cancer Prev 2002;11:125-8.
21. Hennekens CH, Eberlein K. A randomized trial of aspirin and beta-carotene among U.S. physicians. Prev Med 1985;14:165-8.
22. Cook NR, Le IM, Manson JE, et al. Effects of beta-carotene supplementation on cancer incidence by baseline characteristics in the Physicians' Health Study (United States). Cancer Causes Control 2000;11:617-26.
23. Chan JM, Stampfer MJ, Ma J, et al. Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study. Am J Clin Nutr 2001;74:549-54.
24. Catalona WJ, Avioli LV. Diagnosis, staging, and surgical treatment of prostatic carcinoma. Arch Intern Med 1987;147:361-3.
25. Hosmer D, Lemeshow S. Applied logistic regression. New York, NY: John Wiley & Sons, Inc, 1989.
26. Bourke JB, Griffin JP. Diabetes mellitus in patients with benign prostatic hyperplasia. BMJ 1968;4:492-3.
27. Bennett PH. Definition, diagnosis, and classification of diabetes mellitus and impaired glucose tolerance. In: Kahn CR, Weir GC, eds. Joslin's diabetes mellitus. Philadelphia, PA: Lea & Febiger, 1994:193-200.
28. Wingard DL, Barrett-Connor E, Criqui MH, et al. Clustering of heart disease risk factors in diabetic compared to nondiabetic adults. Am J Epidemiol 1983;117:19-26.
29. Tymchuk CN, Tessler SB, Aronson WJ, et al. Effects of diet and exercise on insulin, sex hormone-binding globulin, and prostate-specific antigen. Nutr Cancer 1998;31:127-31.
30. Cerhan JR, Torner JC, Lynch CF, et al. Association of smoking, body mass, and physical activity with risk of prostate cancer in the Iowa 65+ Rural Health Study (United States). Cancer Causes Control 1997;8:229-38.
31. Sesso HD, Gaziano JM, VanDenburgh M, et al. Comparison of baseline characteristics and mortality experience of participants and nonparticipants in a randomized clinical trial: the Physicians' Health Study. Control Clin Trials 2002;23:686-702.
32. Donn AS, Muir CS. Prostatic cancer: some epidemiological features. Bull Cancer 1985;72:381-90.
33. Yatani R, Kusano I, Shiraishi T, et al. Latent prostatic carcinoma: pathological and epidemiological aspects. Jpn J Clin Oncol 1989;19:319-26.
34. Bosland MC. The etiopathogenesis of prostatic cancer with special reference to environmental factors. Adv Cancer Res 1988;51:1-106.
35. Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 1990;143:742-6.
36. Shirai T, Tamano S, Sano M, et al. Site-specific effects of testosterone propionate on the prostate of rat pretreated with 3,2′ -dimethyl-4-aminobiphenyl: dose-dependent induction of invasive carcinomas. Jap J Cancer Res 1995;86:645-8.
37. Mori T, Cui L, Kato K, et al. Direct effects of testosterone, dihydrotestosterone and estrogen on 3,2′-dimethyl-4-aminobiphenyl-induced prostate carcinogenesis in castrated F344 rats. Jap J Cancer Res 1996;87:570-4.
38. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002;94:972-80.
39. Djavan B, Waldert M, Seitz C, et al. Insulin-like growth factors and prostate cancer. World J Urol 2001;19:225-33.
40. Yu H, Berkel H. Insulin-like growth factors and cancer. J La State Med Soc 1999;151:218-23.
41. Iwamura M, Sluss PM, Casamento JB, et al. Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate 1993;22:243-52.
42. Moyad MA, Pienta KJ. Mind-body effect: insulinlike growth factor-1; clinical depression; and breast, prostate, and other cancer risk - an unmeasured and masked mediator of potential significance? Urology 2002;59:4-8.
43. Wolk A, Mantzoros CS, Andersson SO, et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998;90:911-15.
44. Orskov H. Somatostatin, growth hormone, insulin-like growth factor-1, and diabetes: friends or foes? Metabolism 1996;45:91-5.
45. Janssen JA, Lamberts SW. Circulating IGF-1 and its protective role in the pathogenesis of diabetic angiopathy. Clin Endocrinol (Oxf) 2000;52:1-9.